Highlights

  • BIO’s Q2 FY26 revenue reached AUD 6.48 million, representing a 40.9% increase on the prior corresponding period and 9.1% growth on Q1 FY26.
  • H1 FY26 revenue totalled AUD 12.42 million, up 40.2% compared with H1 FY25.
  • Revenue growth was achieved despite Q2 typically being a seasonally softer trading period.

Biome Australia Limited (ASX:BIO) has released its Q2 FY26 trading update, reporting record quarterly and half-year sales. The update outlines continued revenue growth across the December quarter and first half of FY26, driven by increased demand for the Company’s evidence-based probiotic products across domestic and international markets.

Record Quarterly Revenue Delivered in Q2 FY26

For the three months ended December 2025, Biome Australia reported sales revenue of AUD 6.48 million. This compares with AUD 4.6 million recorded in Q2 FY25 and represents a sequential increase from Q1 FY26.

The December quarter is traditionally characterised by fewer trading days and a shift in pharmacy channel focus toward gifting categories during the holiday period. Despite these conditions, Biome delivered its highest quarterly revenue to date, supported by continued product uptake and channel distribution.

Half-Year Sales Reach New High

Half-year revenue for H1 FY26 reached AUD 12.42 million, compared with AUD 8.86 million in the prior corresponding period. The increase reflects consistent sales momentum across the first two quarters of the financial year.

The Company attributed this performance to sustained demand for its clinically supported probiotic range, including products distributed under the Activated Probiotics® brand. Biome continues to focus on practitioner-only distribution channels alongside broader domestic and international sales initiatives.

Product Portfolio and Market Presence

Biome Australia develops, licenses, commercialises and markets live biotherapeutic products and complementary medicines supported by clinical research. Many of its products are underpinned by randomised, double-blind, placebo-controlled trials and target areas including gut health, bone health, iron absorption, mild eczema, sleep and low mood, and irritable bowel syndrome.

Since incorporation in 2018, Biome has expanded its distribution footprint both within Australia and offshore. The Company works with research and development partners in microbiome science to deliver probiotic formulations using proprietary delivery technologies designed to improve stability and efficacy.

Market Snapshot

As at the latest trading update, Biome Australia shares were last traded at AUD 0.455, representing a daily increase of AUD 0.040. Over the past month, the share price has risen by 16.67%. On a one-year basis, the share price has declined by approximately 15.74%.